Abbott Labs

ABT-N

NYSE:ABT

94.92
2.82 (3.06%)
Abbott Laboratories is a multinational health care company with headquarters in Lake Bluff, Illinois.
More at Wikipedia

Analysis and Opinions about ABT-N

Signal
Opinion
Expert
COMMENT
COMMENT
February 9, 2016

Abbott Labs (ABT-N) or Johnson & Johnson (JNJ-N)? She likes healthcare as an overall investment because of the demographics. They both have FX headwinds because they are both international. Emerging markets is about 40% of this company’s revenues. If you want a diversified health care company that gives you an attractive yield, she would go with J&J.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
February 9, 2016

Abbott Labs (ABT-N) or Johnson & Johnson (JNJ-N)? She likes healthcare as an overall investment because of the demographics. They both have FX headwinds because they are both international. Emerging markets is about 40% of this company’s revenues. If you want a diversified health care company that gives you an attractive yield, she would go with J&J.

BUY WEAKNESS
BUY WEAKNESS
February 4, 2016

He likes it. Everything under healthcare has been under pressure. Model $39 with a 3% upside. At $31 he would be very excited.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
February 4, 2016

He likes it. Everything under healthcare has been under pressure. Model $39 with a 3% upside. At $31 he would be very excited.

COMMENT
COMMENT
September 17, 2015

In the healthcare space, he prefers focusing on the health benefit managers such as an Aetna or United Health Group or some names in the biotech space such as Gilead, etc. The valuation on this one looks decent at 20X forward earnings and the growth rate is about 12%. The stock has dropped off quite a bit, so it is not in the space that he likes. (See Top Picks.)

Show full opinionHide full opinion
Abbott Labs (ABT-N)
September 17, 2015

In the healthcare space, he prefers focusing on the health benefit managers such as an Aetna or United Health Group or some names in the biotech space such as Gilead, etc. The valuation on this one looks decent at 20X forward earnings and the growth rate is about 12%. The stock has dropped off quite a bit, so it is not in the space that he likes. (See Top Picks.)

COMMENT
COMMENT
May 5, 2015

Right now this is more if a consumer and diagnostic company. Has done quite well. Is very, very steady. Have increased their dividends 43 years in a row. A nice holding for somebody who wants to buy something and just stay with it over the long-term. However, the valuation is not cheap. Well-managed and should do well over the long-term.

Show full opinionHide full opinion

Right now this is more if a consumer and diagnostic company. Has done quite well. Is very, very steady. Have increased their dividends 43 years in a row. A nice holding for somebody who wants to buy something and just stay with it over the long-term. However, the valuation is not cheap. Well-managed and should do well over the long-term.

BUY WEAKNESS
BUY WEAKNESS
April 27, 2015

He would wait for some sort of correction. Likes this. It is a leader in its field.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
April 27, 2015

He would wait for some sort of correction. Likes this. It is a leader in its field.

COMMENT
COMMENT
March 5, 2015

Has a really good upward trend. It is a little above trend right now. Great long-term chart. Healthcare is a great long-term trend that we are in, and you can’t go wrong. It will probably come back a little bit, but nothing to worry about.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
March 5, 2015

Has a really good upward trend. It is a little above trend right now. Great long-term chart. Healthcare is a great long-term trend that we are in, and you can’t go wrong. It will probably come back a little bit, but nothing to worry about.

PAST TOP PICK
PAST TOP PICK
November 11, 2014

(A Top Pick Oct 29/13. Up 22.2%.) A diversified health company. About 40% of their branded generic business is in emerging markets. They expect to increase that percentage. Also, a large player in the nutritional business. Their 3rd division is medical devices and diagnostics.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
November 11, 2014

(A Top Pick Oct 29/13. Up 22.2%.) A diversified health company. About 40% of their branded generic business is in emerging markets. They expect to increase that percentage. Also, a large player in the nutritional business. Their 3rd division is medical devices and diagnostics.

TOP PICK
TOP PICK
October 14, 2014

Spinning off another division. He loves the drug space, which is free of volatility. His model price is $45, a 10% upside.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
October 14, 2014

Spinning off another division. He loves the drug space, which is free of volatility. His model price is $45, a 10% upside.

PAST TOP PICK
PAST TOP PICK
October 7, 2014

(A Top Pick Oct 29/13. Up 13.13%.) A diversified global healthcare company. They have 4 divisions including brand generics which is more focused on emerging markets. Also, have a nutritional business as well as a stents division along with the diagnostic division. Pays a dividend of about 2%.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
October 7, 2014

(A Top Pick Oct 29/13. Up 13.13%.) A diversified global healthcare company. They have 4 divisions including brand generics which is more focused on emerging markets. Also, have a nutritional business as well as a stents division along with the diagnostic division. Pays a dividend of about 2%.

TOP PICK
TOP PICK
September 17, 2014

His model price is $48.91, a 14% upside. Saw that they are going to spin off another company, the gift that keeps on giving. He loves large-cap drug companies. Yield of 2.02%.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
September 17, 2014

His model price is $48.91, a 14% upside. Saw that they are going to spin off another company, the gift that keeps on giving. He loves large-cap drug companies. Yield of 2.02%.

COMMENT
COMMENT
August 29, 2014

Doesn’t follow this one too closely. Recent reports indicate they are doing a lot of things to restart their growth.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
August 29, 2014

Doesn’t follow this one too closely. Recent reports indicate they are doing a lot of things to restart their growth.

PAST TOP PICK
PAST TOP PICK
July 8, 2014

(Top Pick July 9/13, Up 20.37%) Prefers to stay with this part of the business after the spin out. This is where the growth is. They have branded generics which are a growth area in emerging markets. The just made an acquisition to increase presence in Latin America where pharma should double in the next 5 years.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
July 8, 2014

(Top Pick July 9/13, Up 20.37%) Prefers to stay with this part of the business after the spin out. This is where the growth is. They have branded generics which are a growth area in emerging markets. The just made an acquisition to increase presence in Latin America where pharma should double in the next 5 years.

DON'T BUY
DON'T BUY
April 9, 2014

This one has outperformed the health care sector over the last few years. Sees a 15% growth rate on the dividend, but it is low compared to others. Prefers PFE-N.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
April 9, 2014

This one has outperformed the health care sector over the last few years. Sees a 15% growth rate on the dividend, but it is low compared to others. Prefers PFE-N.

BUY
BUY
February 18, 2014

Growth in large-cap pharmaceutical business is fairly anaemic. There are not a lot of great growth prospects. What he does like about this company is that they have a medical technology business, a nutritionals business as well as a traditional pharmaceutical business i.e. all the components of the healthcare sector. Feels there is some growth from an earnings perspective. (See Top Picks.)

Show full opinionHide full opinion
Abbott Labs (ABT-N)
February 18, 2014

Growth in large-cap pharmaceutical business is fairly anaemic. There are not a lot of great growth prospects. What he does like about this company is that they have a medical technology business, a nutritionals business as well as a traditional pharmaceutical business i.e. all the components of the healthcare sector. Feels there is some growth from an earnings perspective. (See Top Picks.)

BUY
BUY
February 7, 2014

Is this a good time to get into health care stocks and what would you recommend? Likes Abbott Labs (ABT-N) very much. Spun off their pharmaceutical R&D business about 2 years ago and split themselves up into 4 different divisions. If looking at global healthcare companies, you can’t go wrong with something like Johnson & Johnson (JNJ-N). Products are cheap and they can easily raise costs. Also, likes Medtronics (MDT-N) which is a device manufacturer.

Show full opinionHide full opinion
Abbott Labs (ABT-N)
February 7, 2014

Is this a good time to get into health care stocks and what would you recommend? Likes Abbott Labs (ABT-N) very much. Spun off their pharmaceutical R&D business about 2 years ago and split themselves up into 4 different divisions. If looking at global healthcare companies, you can’t go wrong with something like Johnson & Johnson (JNJ-N). Products are cheap and they can easily raise costs. Also, likes Medtronics (MDT-N) which is a device manufacturer.

Showing 31 to 45 of 122 entries